立体定向放射治疗用于早期非小细胞肺癌合并间质性肺病:一项非随机临床试验
这项前瞻性队列研究在6家学术放疗机构纳入39例不适合手术的纤维化间质性肺病合并T1-2N0非小细胞肺癌患者,给予50 Gy/5次隔日立体定向消融放疗。1年总生存率79%,中位总生存25个月,≥3级毒性14%,5级毒性7.7%,达到预设可接受阈值。
要点
- 纤维化间质性肺病合并早期非小细胞肺癌患者接受立体定向消融放疗,1年总生存率79%。
- 中位总生存25个月,中位无进展生存19个月,2年局部控制率92%。
- 3级毒性10%,4级0%,5级7.7%(均因呼吸功能恶化)。
核心结论
- 在纤维化间质性肺病患者中,立体定向消融放疗达到了预设的毒性和疗效可接受阈值,支持在仔细讨论风险与获益后用于根治性治疗。
研究设计与样本
- 前瞻性队列研究,在6家学术放疗机构开展(加拿大5家、苏格兰1家),入组时间为2019年3月7日至2022年1月12日。
- 纳入39例18岁及以上、纤维化间质性肺病合并T1-2N0非小细胞肺癌、不适合手术切除的患者,均接受立体定向消融放疗50 Gy/5次隔日照射,采用意向性治疗分析。
主要发现
- 中位随访19个月(IQR 14-25),1年总生存率79%(95%CI 62%-89%;P<.001 vs 不可接受率),中位总生存25个月(95%CI 14个月至未达到)。
- 中位无进展生存19个月(95%CI 13-28个月),2年局部控制率92%(95%CI 69%-98%)。
- 不良事件最高分级:1-2级12例(31%),3级4例(10%),4级0例,5级3例(7.7%,均因呼吸功能恶化)。
- 基线时70%(26/37)患者报告呼吸困难,中位第一秒用力呼气容积为预测值80%(IQR 66%-90%),中位用力肺活量为预测值84%(IQR 69%-94%),中位一氧化碳弥散量为预测值49%(IQR 38%-61%)。
关键数值与推荐
- 研究预设立体定向消融放疗值得进行的标准:中位总生存(主要终点)超过1年,3-4级毒性风险低于35%,5级毒性风险低于15%。
临床怎么用
- 作者认为,在仔细讨论风险与获益后,立体定向消融放疗可用于纤维化间质性肺病合并早期非小细胞肺癌患者的根治性治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with interstitial lung disease (ILD) and early-stage non-small cell lung cancer (NSCLC) have been reported to be at high risk of toxic effects after stereotactic ablative radiotherapy (SABR), but for many patients, there are limited alternative treatment options. OBJECTIVE: To prospectively assess the benefits and toxic effects of SABR in this patient population. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was conducted at 6 academic radiation oncology institutions, 5 in Canada and 1 in Scotland, with accrual between March 7, 2019, and January 12, 2022. Patients aged 18 years or older with fibrotic ILD and a diagnosis of T1-2N0 NSCLC who were not candidates for surgical resection were enrolled. INTERVENTION: Patients were treated with SABR to a dose of 50 Gy in 5 fractions every other day. MAIN OUTCOMES AND MEASURES: The study prespecified that SABR would be considered worthwhile if median overall survival-the primary end point-was longer than 1 year, with a grade 3 to 4 risk of toxic effects less than 35% and a grade 5 risk of toxic effects less than 15%. Secondary end points included toxic effects, progression-free survival (PFS), local control (LC), quality-of-life outcomes, and changes in pulmonary function. Intention-to-treat analysis was conducted. RESULTS: Thirty-nine patients enrolled and received SABR. Median age was 78 (IQR, 67-83) years and 59% (n = 23) were male. At baseline, 70% (26 of 37) of patients reported dyspnea, median forced expiratory volume in first second of expiration was 80% (IQR, 66%-90%) predicted, median forced vital capacity was 84% (IQR, 69%-94%) predicted, and median diffusion capacity of the lung for carbon monoxide was 49% (IQR, 38%-61%) predicted. Median follow-up was 19 (IQR, 14-25) months. Overall survival at 1 year was 79% (95%, CI 62%-89%; P < .001 vs the unacceptable rate), and median overall survival was 25 months (95% CI, 14 months to not reached). Median PFS was 19 months (95% CI, 13-28 months), and 2-year LC was 92% (95% CI, 69%-98%). Adverse event rates (highest grade per patient) were grade 1 to 2: n = 12 (31%), grade 3: n = 4 (10%), grade 4: n = 0, and grade 5: n = 3 (7.7%, all due to respiratory deterioration). CONCLUSIONS AND RELEVANCE: In this trial, use of SABR in patients with fibrotic ILD met the prespecified acceptability thresholds for both toxicity and efficacy, supporting the use of SABR for curative-intent treatment after a careful discussion of risks and benefits. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03485378.
引用
- Palma DA, Bahig H, Hope A, et al. Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical Trial. JAMA Oncol. 2024. PMID: 38451491. doi:10.1001/jamaoncol.2023.7269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。